Pharmaceutical R&D Outsourcing: Best Practices, Trends and Predictions
Webcast Recording Date: December 10, 2010
Duration: approximately 1 hour
Presenters: Michael J. Muller – Assistant General Counsel, Commercial Transactions, Eli Lilly
Vicki Phelan, Managing Director - Pharmaceutical and Life Sciences, EquaTerra
Mark Stark, Contract Architecture and Negotiation Specialist, EquaTerra
Natalie Kingston, Associate – Outsourcing Practice, Morgan, Lewis & Bockius LLP
Description: The pharmaceutical industry has traditionally been one of the most progressive andmature industries in its use of outsourcing, whether for selling, general, and administrative (SG&A) functions or discrete functions within research and development (R&D). While R&D outsourcing (RDO) has often been smaller in scope, within the past two years it has expanded into regulatory outsourcing and some of the more progressive pharmaceutical organizations have both considered and implemented this expanded scope in their R&D functions. In this informative webcast, our outsourcing industry panelists explores RDO’s past, present, and future.
Key discussion points include::
- The State of the RDO Market
- Service Delivery Models – Determining the Best One for Your Organization
- Regulatory Outsourcing – Benefits, Considerations and Risks
- How to Safely Optimize RDO Through Controls and Risk Mitigation
- Evolution of the R&D Market – What’s Next?
Click here to listen to the recording.
|
